Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis

Inclusion Criteria: * Patients who sign the IC in two ways, agreeing with all study procedures * Patients aged above 18 years of any ethnicity, class or social group, female or male * Patients with acute, subacute or chronic dermatoses, of inflammatory and / or allergic origin, to which it is recommended the use of drugs under investigation, such as: * atopic dermatitis * prurigo * primary contact dermatitis or allergic hives * drug eruption * allergic vasculitis * dyshidrosis, Note: The above clinical conditions are diagnosed from clinical examination. Exclusion Criteria: * Patients being treated with antibiotics * Participation in clinical trials in the 12 months preceding the investigation * Current treatment with immunosuppressants (eg, cyclosporine or methotrexate) * Current treatment with phototherapy (UVA, UVB, PUVA and lasers) * Use of systemic corticosteroids in the visit to include or 15 days preceding the survey * Topical treatments at the site of lesions in the 15 days preceding the survey * Presence of any skin condition * Presence of secondary infections at the site of treatment, diagnosed clinically; * Presence of other eczematous diseases, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome * Pregnant or lactating women * Chronic alcoholism * Patients with a history of hypersensitivity to any component of the products under investigation. * Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study. * Allergic Dermatosis mild or, acording to the investigator criteria, is not justified systemic treatment.